Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05461430

Acronym

TraveraRTGx

Enrollment

Registered

2022-07-18

Start date

2022-07-15

Completion date

2026-03-23

Last updated

2026-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ascites, Malignant, Carcinoma, Carcinoma Bladder, Carcinoma Breast, Carcinoma, Hepatocellular, Carcinoma, Neuroendocrine, Carcinoma, Non-Small-Cell Lung, Carcinoma of Esophagus, Carcinoma of the Anus, Carcinoma of the Appendix, Carcinoma of the Bladder, Carcinoma of the Cervix, Carcinoma of the Head and Neck, Carcinoma of the Larynx, Carcinoma of the Nasopharynx, Carcinoma of the Oral Cavity, Carcinoma of the Oropharynx, Carcinoma of the Penis, Carcinoma of the Vulva, Carcinoma of Unknown Primary, Carcinoma, Ovarian, Carcinoma, Pancreatic, Carcinoma, Pancreatic Ductal, Carcinoma, Renal, Carcinoma, Renal Cell, Carcinoma, Small Cell, Carcinoma, Thymic, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer, Pleural Effusion, Malignant

Keywords

Breast Cancer, Lung Cancer, NSCLC, Occult Cancer, Ovarian Cancer, Melanoma, Mesothelioma, Gastrointestinal Stromal Tumor, Gastric Cancer, Colon Cancer, Cervical Cancer

Brief summary

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patient is ≥18 years of age 2. Written Informed Consent provided by patient 3. Diagnosis of any kind of carcinoma 4. Malignant fluid (e.g. pleural effusion or ascites) drainage OR tumor tissue resection OR tumor tissue needle biopsy is clinically indicated as part of SOC 5. Proceeding onto therapy for treatment 6. Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088)

Exclusion criteria

1. Lack of informed consent 2. Unable to obtain sufficient sample

Design outcomes

Primary

Measure	Time frame	Description
BOR	12 months	Best overall response

Secondary

Measure	Time frame	Description
PFS	24 months	Progression Free Survival

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORMark Stevens, Phd

Travera Inc

PRINCIPAL_INVESTIGATORRob Kimmerling, Phd